Real-World Treatment Duration in ALK-Positive Non-Small-Cell Lung Cancer Patients Receiving Brigatinib Through the Early Access Program

Figures & data

Table 1. Baseline characteristics of patients in the brigatinib early access program.

Characteristics	Patients (n = 604)
Age, median (range)	58.0 (19–94)
Gender
Males	256 (42.4)
Females	343 (56.8)
Missing	5 (0.8)
Latest performance status
0	205 (33.9)
1	314 (52.0)
2	49 (8.1)
Missing	36 (6.0)
Number of prior ALK TKIs
1	155 (25.7)
2	209 (34.6)
3+	69 (11.5)
Missing	171 (28.3)
Prior ALK TKI
Alectinib	8 (1.3)
Alectinib + Ceritinib	3 (0.5)
Alectinib + Ensartinib	1 (0.2)
Ceritinib	28 (4.6)
Ceritinib + Lorlatinib	2 (0.3)
Crizotinib	117 (19.4)
Crizotinib + Alectinib	43 (7.1)
Crizotinib + Alectinib + Ceritinib	38 (6.3)
Crizotinib + Alectinib + Ceritinib + Lorlatinib	10 (1.7)
Crizotinib + Alectinib + Lorlatinib	8 (1.3)
Crizotinib + Ceritinib	155 (25.7)
Crizotinib + Ceritinib + Lorlatinib	13 (2.2)
Crizotinib + Ensartinib	1 (0.2)
Crizotinib + Lorlatinib	4 (0.7)
Ensartinib	1 (0.2)
Entrectinib	1 (0.2)
Missing	171 (28.3)
Most recent ALK TKI
Alectinib	79 (13.1)
Ceritinib	178 (29.5)
Crizotinib	115 (19.0)
Crizotinib + Ceritinib	1 (0.2)
Ensartinib	3 (0.5)
Entrectinib	1 (0.2)
Lorlatinib	31 (5.1)
Missing	196 (32.5)

Data represented as n (%), unless otherwise stated.

EAP: Early access program; TKI: Tyrosine kinase inhibitor.

Figure 1. Probability of continued use of brigatinib across all lines of therapy.

Figure 2. Brigatinib use among patients with prior alectinib.

(A) Patients with prior alectinib as any line. (B) Patients with alectinib as most recent ALK TKI. (C) Patients with crizotinib + alectinib or alectinib alone. (D) Patients with ≥1 other NG ALK TKI in addition to alectinib. (E) Median brigatinib TTD among patients with prior alectinib.

NG: Next-generation; TKI: Tyrosine kinase inhibitor; TTD: Time-to-treatment discontinuation.

Figure 3. Brigatinib use among patients with prior ALK tyrosine kinase inhibitors.

(A) Patients with prior crizotinib as any line. (B) Patients with prior crizotinib alone. (C) Patients with prior ceritinib as any line. (D) Patients with prior lorlatinib as any line. (E) Median brigatinib TTD among patients with prior crizotinib or lorlatinib.

NE: Not evaluable; TKI: Tyrosine kinase inhibitor; TTD: Time-to-treatment discontinuation.

Figure 4. Brigatinib use by number of prior ALK tyrosine kinase inhibitors.

(A) Patients with one to three prior ALK TKIs. (B) Median brigatinib TTD by number of prior ALK inhibitors.

NE: Not evaluable; TKI: Tyrosine kinase inhibitor; TTD: Time-to-treatment discontinuation.

Table 2. Reasons for brigatinib treatment discontinuation.

Reasons for treatment discontinuation	n (%)
Total patients	604
Discontinued	260 (43.0)
Adverse event	4 (0.7)
Disease progression	64 (10.6)
Death	15 (2.5)
Lost to follow-up	1 (0.2)
Other	31 (5.1)
Assumed discontinued (discontinuation defined by gap)^†	145 (24.0)

^† Discontinuation was assumed for patients without confirmed discontinuation if there was a gap of >120 days between data cutoff date (7 November 2018) and last medication shipment date. Discontinuation date was last shipment date plus 30 days.